The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
Written by
in